In this review:
This review discusses evidence in support of the use of oral Alecensa® (alectinib) for the treatment of anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC). Alectinib is a highly selective, central nervous system (CNS)-active ALK inhibitor. In New Zealand, it is indicated for the treatment of adult patients with ALK-positive, locally advanced or metastatic NSCLC.1 This publication has been commissioned by Roche Products (New Zealand) Limited.
Please login below to download this issue (PDF)